Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital

Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.

Ace Pharmaceuticals is a leading pharmaceutical company in the niche of medical need products, and is based in Zeewolde, the Netherlands. As an independent company, Ace focuses on the development, production and distribution of licensed and unlicensed medicines. With its activities, Ace meets an essential social need: making and keeping scarce medication available for people for whom it is essential. It does so by actively collaborating with relevant stakeholders, including patient associations, doctors and governmental institutions. Since January 2020, Ace has also been supplying pharmaceutical compounding products to pharmacies in the Netherlands through its business unit Ace Compounding.

Oaklins’ debt advisory team in the Netherlands acted as advisor to the consortium and assisted in establishing a financing package aligned with the current business profile and future growth ambitions.

Uppdrag

Kapitalanskaffning, finansiering och ECM

Parter

“The COVID-19 pandemic has clearly highlighted the challenges and gaps in our industry in Europe. It makes our mission to make scarce medicines available more important than ever. We want to respond to this situation strongly by growing organically as well as through acquisitions in Europe. With the capital, the know-how and the broad (international) network of Gilde Buy Out Partners, Gilde Healthcare, and our existing investor Quadrum Capital, we can achieve this in both a socially responsible as well as financially sound manner.”

Jan Willem Popma

Director, Ace Pharmaceuticals BV

Prata med transaktionsteamet

Bas Stoetzer

Partner

Amsterdam, Nederländerna
Oaklins Netherlands

Se profil Kontakta oss

Niels Vermuë

Associate Director

Amsterdam, Nederländerna
Oaklins Netherlands

Se profil Kontakta oss

Relaterade transaktioner

Bayer AG has entered into a takeover agreement with Cara Care

Hälsovård | TMT

Bayer AG has entered into a takeover agreement with Cara Care

Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.

Lär dig mer

Mark Climate Technology has acquired Heber GmbH

Riskkapital | Industriella maskiner och komponenter | Andra industrier

Mark Climate Technology has acquired Heber GmbH

Heber GmbH has been acquired by Mark Climate Technology, a specialist in climate control systems and a portfolio company of Bolster Investment Partners. This partnership strengthens the positions of both companies in the global market for innovative and sustainable climate solutions, as well as creating unique synergies. Mark Climate's expertise in standardized, scalable solutions is enhanced by Heber's emphasis on customer-specific customization.

Lär dig mer

Grupo Veta 2017 S.L. has been acquired by MSA Mizar

Riskkapital | Företagstjänster | Finansiella tjänster | TMT

Grupo Veta 2017 S.L. has been acquired by MSA Mizar

The Franco-Belgian fund Kartesia has sold Grupo Veta 2017 S.L. to the Italian group MSA Mizar. Kartesia, the main shareholder of Veta+ together with its founding partner, has sold 100% of the capital. For MSA Mizar, this transaction represents the consolidation of its presence in Spain, the entry into the multi-risk claims management market and the opportunity to apply Veta+’s expertise to other European markets.

Lär dig mer